9 studies found for:    cKIT inhibitors | "Melanoma"
Show Display Options
Rank Status Study
1 Active, not recruiting SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: Sunitinib
2 Completed cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Condition: Melanoma
Intervention: Other: sequencing
3 Unknown  A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: nilotinib
4 Active, not recruiting Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Acral Lentiginous Malignant Melanoma;   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
5 Active, not recruiting Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Melanoma;   Acral/Lentiginous Melanoma;   Chronically Sun Damaged Melanomas
Intervention: Drug: Imatinib
6 Completed Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Imatinib (Gleevec)
7 Terminated Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Condition: Melanoma
Interventions: Drug: Dasatinib;   Procedure: Surgical Resection
8 Recruiting A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Condition: Melanoma
Interventions: Drug: imatinib;   Drug: Interferon
9 Completed Clinical Trial of Sutent to Treat Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Sutent (sunitinib)

Indicates status has not been verified in more than two years